ArticleTargeted oncology2023

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.

David Elsea et al.PubMed ↗Publisher ↗

No numbers read from the abstract.